Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2013

01-03-2013 | Review Article

Hepatitis C infection and chronic renal diseases

Author: Aline Gonzalez Vigani

Published in: Hepatology International | Issue 1/2013

Login to get access

Abstract

Hepatitis C virus (HCV) infection and chronic renal diseases can be linked in two different ways. Some forms of renal disease are precipitated by HCV infection, while patients with end-stage renal disease are at increased risk for acquiring HCV infection. Patients with chronic HCV infection and renal disease have a poor prognosis. Most studies on treatment of HCV and renal diseases have been uncontrolled trials with small number of subjects. So, there is a lack of evidence-based recommendations and guidelines on the management of this condition. In this review, we will attempt to provide the most recent insights on HCV infection both as a extrahepatic manifestations and as a complication of end-stage renal patients.
Literature
1.
Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1–16PubMedCrossRef
2.
3.
Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002;22:309–318PubMed
4.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–567PubMedCrossRef
5.
Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65:2335–2342PubMedCrossRef
6.
Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3–10PubMedCrossRef
7.
Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004;20:1271–1277PubMedCrossRef
8.
USDR. US Renal Data System: Excerpts from the USDR 2006. Annual Data Report.
9.
Sansonno D, Carbone A, De Re V, et al. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007;46:572–578CrossRef
10.
D’Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995;25:361–369PubMedCrossRef
11.
Dammacco F, Sansonno D, Piccoli C, et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000;20:143–157PubMedCrossRef
12.
Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291–1300PubMed
13.
Vigani AG, Macedo de Oliveira A, Tozzo R, et al. The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C. J Viral Hepat 2010;18:e91–e98PubMedCrossRef
14.
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490–1495PubMedCrossRef
15.
Nagasaka A, Takahashi T, Sasaki T, et al. Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study. J Med Virol 2001;65:52–57PubMedCrossRef
16.
Barsoum RS. Hepatitis C virus: from entry to renal injury—facts and potentials. Nephrol Dial Transplant 2007;22:1840–1848PubMedCrossRef
17.
Stokes MB. Immune complex glomerulonephritis in patients with hepatitis C. Saudi J Kidney Dis Transpl 2000;11:396–404PubMed
18.
Fabrizi F, Lunghi G, Messa P, et al. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008;21:813–825PubMed
19.
Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465–470PubMedCrossRef
20.
Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700–1704CrossRef
21.
Chacko EC, Surrun SK, Mubarack Sani TP, et al. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J 2010;86:486–492PubMedCrossRef
22.
Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618–623PubMedCrossRef
23.
Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69–82PubMedCrossRef
24.
Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003;42:631–657PubMedCrossRef
25.
Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436–439PubMedCrossRef
26.
Perico N, Cattaneo D, Bikbov B, et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207–220PubMedCrossRef
27.
Ferri C, Moriconi L, Gremignai G, et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246–253PubMedCrossRef
28.
Singer DR, Venning MC, Lockwood CM, et al. Cryoglobulinaemia: clinical features and response to treatment. Ann Med Interne 1986;137:251–253
29.
Frankel AH, Singer DR, Winearls CG, et al. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992;82:101–124PubMed
30.
De Vecchi A, Montagnino G, Pozzi C, et al. Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983;19:221–227PubMed
31.
Sinico RA, Fornasieri A, Fiorini G, et al. (1985) Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up. Int J Artif Organs 8(Suppl 2):15–18
32.
Bombardieri S, Ferri C, Paleologo G, et al. Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 1983;6(Suppl 1):47–50PubMed
33.
Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054–3061PubMedCrossRef
34.
Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842–846PubMedCrossRef
35.
Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38:2308–2310PubMedCrossRef
36.
Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transp 2003;9:S63–S66CrossRef
37.
Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196–199PubMed
38.
Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056–1063PubMedCrossRef
39.
Bjøro K, Skaug K, Haaland T, et al. Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM 1999;92:433–441PubMedCrossRef
40.
Bestard O, Cruzado JM, Ercilla G, et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006;21:2320–2324PubMedCrossRef
41.
Bruchfeld A, Saadoun D, Cacoub P. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia–anti-viral therapy versus rituximab. Rheumatology (Oxford) 2006;45:783–784CrossRef
42.
Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818–3826PubMedCrossRef
43.
Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995;44:141–147PubMed
44.
Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease. Nephrol Dial Transplant 2003;18:1573–1580PubMedCrossRef
45.
Lopes EP, Valente LM, Silva AE, et al. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003;7:353–357PubMedCrossRef
46.
Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006;54:3696–3706PubMedCrossRef
47.
Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617–623PubMedCrossRef
48.
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958–965PubMedCrossRef
49.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982PubMedCrossRef
50.
Hadziyannis SJ, Sette H Jr, Morgan TR, PEGASYS International Study Group, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355PubMed
51.
Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007;30:212–219PubMed
52.
Ghany MG, Strader DB, Thomas DL, et al. American association for the study of liver diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374PubMedCrossRef
53.
Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109–1115PubMedCrossRef
54.
Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48:1690–1699PubMedCrossRef
55.
Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat 2001;8:287–292PubMedCrossRef
56.
Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001;16:193–195PubMedCrossRef
57.
Mousa DH, Abdalla AH, Al-Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004;36:1831–1834PubMedCrossRef
58.
Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;46:563–570PubMedCrossRef
59.
Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006;29:1013–1017CrossRef
60.
Mangia A, Burra P, Ciancio A, Italian Association for The Study of The Liver (AISF), et al. Hepatitis C infection in patients with chronic kidney disease. Int J Artif Organs 2008;31:15–33PubMed
61.
Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998;36:1711–1715PubMed
62.
Hanuka N, Sikuler E, Tovbin D, et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002;9:141–145PubMedCrossRef
63.
Dalekos GN, Boumba DS, Katopodis K, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 1998;13:1804–1806PubMedCrossRef
64.
Okuda K, Hayashi H, Yokozeki K, et al. Destruction of hepatitis C virus particles by haemodialysis. Lancet 1996;347:909–910PubMedCrossRef
65.
66.
Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008;18:97–115PubMedCrossRef
67.
Pawa S, Ehrinpreis M, Mutchnick M, et al. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007;5:1316–1320PubMedCrossRef
68.
Ozdogan M, Ozgur O, Boyacioplu S, et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996;74:442–443PubMedCrossRef
69.
Ahmad A, Hasan F, Abdeen S, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004;15:257–260PubMedCrossRef
70.
Poynard T, Imbert-Bismut F, Ratziu V, GERMED cyt04 group, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepatitis 2002;9:128–133CrossRef
71.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48–54PubMedCrossRef
72.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589–2600PubMedCrossRef
73.
Varaut A, Fontaine H, Serpaggi J, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550–1555PubMedCrossRef
74.
Cotler SJ, Diaz G, Diaz G. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002;35:191–195PubMedCrossRef
75.
Martin P, Carter D, Carter D. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000;69:1479–1484PubMedCrossRef
76.
Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999;94:3576–3582PubMedCrossRef
77.
Di Napoli A, Pezzotti P, Di Lallo D, et al. Lazio Dialysis Registry Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006;48:629–637PubMedCrossRef
78.
Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896–1902PubMed
79.
Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003;14:3270–3277PubMedCrossRef
80.
Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007;18:1584–1593PubMedCrossRef
81.
Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:1452–1461PubMedCrossRef
82.
Roth D, Cirocco R, Reddy R. (2002) Ten year prospective study of hepatitis C virus infection in kidney transplant recipients. Am J Transpl 2:abstract no. 260A
83.
Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471–476PubMedCrossRef
84.
Legendre CH, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C infection in kidney transplant recipients. Transplantation 1998;65:667–670PubMedCrossRef
85.
Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–263PubMedCrossRef
86.
Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002;74:427–437PubMedCrossRef
87.
Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997;29:608–614PubMedCrossRef
88.
Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071–1081PubMedCrossRef
89.
Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610–1615PubMedCrossRef
90.
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426–1432PubMedCrossRef
91.
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;19:1485–1492CrossRef
92.
Fabrizi F, Dixit V, Messa P, et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008;15:79–88PubMed
93.
Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kid Dis 2010;4:181–194
94.
Gordon CE, Uhlig K, Lau J, et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kid Dis 2008;51:263–277PubMedCrossRef
95.
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–S244PubMedCrossRef
96.
Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006;26:305–310PubMedCrossRef
97.
Huraib S, Tanimu D, Romeh SA, et al. Interferon-α in chronic hepatitis C infection in dialysis patients. Am J Kid Dis 1999;34:55–60PubMedCrossRef
98.
Fernandez JL, Rendo P, Del Pino N. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepat 1997;4:113–119PubMed
99.
Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525–530PubMedCrossRef
100.
Ayaz C, Celen MK, Yuce UN, et al. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008;14:255–259PubMedCrossRef
101.
Casanovas-Taltavull T, Baliellas C, Llobet M, et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007;39:2125–2127PubMedCrossRef
102.
van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alpha-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:721–725PubMedCrossRef
103.
Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alpha-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768–774PubMedCrossRef
104.
Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19:17–24PubMed
105.
Mihm U, Herrmann E, Sarrazin C, et al. Review article: Predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006;23:1043–1054PubMedCrossRef
106.
Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821–829PubMedCrossRef
107.
Degos F, Pol S. The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001;16:1017–1023PubMedCrossRef
108.
Hanrotel C, Toupance O, Toupance O. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001;88:120–126PubMedCrossRef
109.
Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 2006;130:1086–1097PubMedCrossRef
Metadata
Title
Hepatitis C infection and chronic renal diseases
Author
Aline Gonzalez Vigani
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 1/2013
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-012-9356-5

Other articles of this Issue 1/2013

Hepatology International 1/2013 Go to the issue

Original Article

A nationwide population-based study shows increasing incidence of cholangiocarcinoma

Original Article

Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome

Original Article

The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study

Original Article

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay

Original Article

Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients

Original Article

Short hairpin RNAs with a 2- or 3-base mismatch inhibit HBV expression and replication in HepG2 cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits